Trial · NCT06535529
Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients
NCT06535529, Phase 3, Unknown, Helwan University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients. Trials, record NCT06535529. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06535529
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients
- NCT number
- NCT06535529
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Helwan University
- Conditions
- Acute Decompensated Heart Failure
- Interventions
- Acetazolamide, Dapagliflozin 10mg
- First posted
- 2024-08-02
- Last updated
- 2024-08-05
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | N-terminal pro-B-type natriuretic peptide (NT-proBNP) | From baseline to day 5 or intensive care unit (ICU) discharge, whichever occurs first | Absolute change in NT-proBNP levels from baseline to end of study period |
| Primary | calculating of weight loss Loop diuretic efficiency | 72 hours from initiation of treatment | Weight loss (in kg) per 40 mg of intravenous furosemide or equivalent dose of other loop diuretics |
| Secondary | Number of Participants with Successful decongestion | 72 hours from initiation of treatment | Proportion of patients achieving an ADVOR Score ≤ 1 without the need for escalating diuretic strategy (defined as doubling loop diuretic dose, addition of chlorthalidone, or ultrafiltration) |
| Secondary | Duration of the index hospital admission | From date of randomization until the date of discharge or date of death from any cause, whichever came first, assessed up to 100 weeks | Number of days from randomization until the date of discharge |
| Secondary | 30-day mortality | Up to 30 days | Proportion of patients who die from any cause within 30 days of randomization |
| Secondary | Cumulative dose of intravenous loop diuretics | 5 days | Total milligrams of intravenous furosemide or equivalent dose of other loop diuretics administered |
| Secondary | Incidence of treatment-related metabolic acidosis | 5 days | Proportion of patients developing metabolic acidosis requiring sodium bicarbonate (NaHCO3) supplementation |
| Secondary | percent of worsening renal failure (WRF) | up to 4 weeks | Proportion of patients experiencing either: a) An increase in serum creatinine \> 0.3 mg/dL from baseline, or b) A decrease in estimated glomerular filtration rate (eGFR) \> 20% from baseline |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06535529
GET https://conductscience.org/api/trials/v1/NCT06535529/registered